- Home
- AYTU
AYTU
Aytu BioPharma Inc.
as 10-08-2025 4:00pm EST
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | DENVER |
| Market Cap: | 18.8M | IPO Year: | N/A |
| Target Price: | $9.17 | AVG Volume (30 days): | 393.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.16 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.95 - $2.82 | Next Earning Date: | 11-12-2025 |
| Revenue: | $66,382,000 | Revenue Growth: | 1.84% |
| Revenue Growth (this year): | -4.26% | Revenue Growth (next year): | 19.03% |
Latest Aytu BioPharma Inc. News
AYTU Breaking Stock News: Dive into AYTU Ticker-Specific Updates for Smart Investing
ACCESS Newswire
22 days ago
Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025
ACCESS Newswire
3 months ago
Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)
Simply Wall St.
4 months ago
CEO & Director of Aytu BioPharma Joshua Disbrow Buys 77% More Shares
ACCESS Newswire
4 months ago
Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan
Pharmaceutical Technology
4 months ago
Aytu BioPharma to commercialise Exxua for MDD in the US
ACCESS Newswire
4 months ago
Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock
ACCESS Newswire
4 months ago
Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States
Simply Wall St.
5 months ago
Aytu BioPharma Third Quarter 2025 Earnings: Beats Expectations
Compare AYTU vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AYTU Aytu BioPharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.